88 related articles for article (PubMed ID: 12717401)
1. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C.
Ulsenheimer A; Gerlach JT; Gruener NH; Jung MC; Schirren CA; Schraut W; Zachoval R; Pape GR; Diepolder HM
Hepatology; 2003 May; 37(5):1189-98. PubMed ID: 12717401
[TBL] [Abstract][Full Text] [Related]
2. Frequency of the Main Human Leukocyte Antigen A, B, DR, and DQ Loci Known to Be Associated with the Clearance or Persistence of Hepatitis C Virus Infection in a Healthy Population from the Southern Region of Morocco: A Preliminary Study.
Machraoui S; Errafii K; Oujamaa I; Belghali MY; Hakmaoui A; Lamjadli S; Eddehbi FE; Brahim I; Haida Y; Admou B
Diseases; 2024 May; 12(5):. PubMed ID: 38785761
[TBL] [Abstract][Full Text] [Related]
3. TGF-β blocking combined with photothermal therapy promote tumor targeted migration and long-term antitumor activity of CAR-T cells.
Tang Y; Yao W; Hang Hu ; Xiong W; Mei H; Hu Y
Mater Today Bio; 2023 Jun; 20():100615. PubMed ID: 37063775
[TBL] [Abstract][Full Text] [Related]
4. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.
Sepulveda-Crespo D; Resino S; Martinez I
Drugs; 2021 Mar; 81(4):419-443. PubMed ID: 33400242
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus.
Bonilla CM; McGrath NA; Fu J; Xie C
Hepatoma Res; 2020; 6():. PubMed ID: 33134550
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C Virus Vaccine: Challenges and Prospects.
Duncan JD; Urbanowicz RA; Tarr AW; Ball JK
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32079254
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T cell responses in human viral infection: lessons from hepatitis C.
Binder B; Thimme R
J Clin Invest; 2020 Feb; 130(2):595-597. PubMed ID: 31904589
[TBL] [Abstract][Full Text] [Related]
8. Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination.
Smits M; Zoldan K; Ishaque N; Gu Z; Jechow K; Wieland D; Conrad C; Eils R; Fauvelle C; Baumert TF; Emmerich F; Bengsch B; Neumann-Haefelin C; Hofmann M; Thimme R; Boettler T
J Clin Invest; 2020 Feb; 130(2):998-1009. PubMed ID: 31697649
[TBL] [Abstract][Full Text] [Related]
9. A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice.
Dawood RM; Moustafa RI; Abdelhafez TH; El-Shenawy R; El-Abd Y; Bader El Din NG; Dubuisson J; El Awady MK
BMC Infect Dis; 2019 Nov; 19(1):932. PubMed ID: 31690267
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.
Villani R; Vendemiale G; Serviddio G
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583555
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D.
Konstantinides P; Alexopoulou A; Hadziyannis E; Kanellopoulou T; Dourakis SP
Ann Gastroenterol; 2018; 31(6):705-711. PubMed ID: 30386121
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.
Cho H; Kang H; Lee HH; Kim CW
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703774
[TBL] [Abstract][Full Text] [Related]
13. Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4
Muraro E; Merlo A; Martorelli D; Cangemi M; Dalla Santa S; Dolcetti R; Rosato A
Front Immunol; 2017; 8():197. PubMed ID: 28289418
[TBL] [Abstract][Full Text] [Related]
14. The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C.
Cachem FCOF; Dias AS; Monteiro C; Castro JR; Fernandes G; Delphim L; Almeida AJ; Tavares F; Maciel AMA; Amendola-Pires MM; Brandão-Mello CE; Bento CAM
Immunology; 2017 Jun; 151(2):167-176. PubMed ID: 28140446
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.
Meng P; Zhao S; Niu X; Fu N; Su S; Wang R; Zhang Y; Qiao L; Nan Y
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428948
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma.
Ouaguia L; Morales O; Mrizak D; Ghazal K; Boleslawski E; Auriault C; Pancré V; de Launoit Y; Conti F; Delhem N
ISRN Hepatol; 2013; 2013():928485. PubMed ID: 27335834
[TBL] [Abstract][Full Text] [Related]
17. Host-virus interactions in hepatitis B and hepatitis C infection.
Yoshio S; Kanto T
J Gastroenterol; 2016 May; 51(5):409-20. PubMed ID: 26894594
[TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis of Hepatitis C Virus Infection.
Kaplan DE
Gastroenterol Clin North Am; 2015 Dec; 44(4):735-60. PubMed ID: 26600217
[TBL] [Abstract][Full Text] [Related]
19. Different aspects of CD4 T cells that lead to viral clearance or persistence of HCV infection.
Sugimoto K; Shiraki K
Hepatol Int; 2012 Jan; 6(1):350-5. PubMed ID: 26201340
[TBL] [Abstract][Full Text] [Related]
20. T-cell responses in hepatitis B and C virus infection: similarities and differences.
Schmidt J; Blum HE; Thimme R
Emerg Microbes Infect; 2013 Mar; 2(3):e15. PubMed ID: 26038456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
